Andrew Lukowiak - Talis Biomedical President Officer
President
Andrew Lukowiak is President Officer of Talis Biomedical Corp
| Age | 51 |
| Phone | 650 433 3000 |
| Web | https://talisbio.com |
Andrew Lukowiak Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Lukowiak against Talis Biomedical pink sheet is an integral part of due diligence when investing in Talis Biomedical. Andrew Lukowiak insider activity provides valuable insight into whether Talis Biomedical is net buyers or sellers over its current business cycle. Note, Talis Biomedical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Talis Biomedical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Lukowiak over three months ago Acquisition by Andrew Lukowiak of 30575 shares of Talis Biomedical at 7.42 subject to Rule 16b-3 |
Talis Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.2959) % which means that it has lost $0.2959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7048) %, meaning that it created substantial loss on money invested by shareholders. Talis Biomedical's management efficiency ratios could be used to measure how well Talis Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Talis Biomedical Corp currently holds 19.67 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Talis Biomedical Corp has a current ratio of 12.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Talis Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Talis Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Talis Biomedical Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Talis to invest in growth at high rates of return. When we think about Talis Biomedical's use of debt, we should always consider it together with cash and equity.
Talis Biomedical Corporation operates as a molecular diagnostic company. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. Talis Biomedical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. Talis Biomedical Corp [TLIS] is a Pink Sheet which is traded between brokers as part of OTC trading. Talis Biomedical is listed under Measuring and Control Equipment category by Fama And French industry classification. Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 |
Talis Biomedical Corp Leadership Team
Elected by the shareholders, the Talis Biomedical's board of directors comprises two types of representatives: Talis Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Talis. The board's role is to monitor Talis Biomedical's management team and ensure that shareholders' interests are well served. Talis Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Talis Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Moody, Chief Officer | ||
| Gillian Green, Company Secretary | ||
| Margaret MS, Controller | ||
| Rustem Ismagilov, CoFounder Director | ||
| Rebecca Markovich, Interim Officer | ||
| Jill Green, Senior Legal | ||
| Andrew Lukowiak, President Officer | ||
| MBA Moody, Chief Officer | ||
| Robert MBA, CEO Director | ||
| Liang Li, CoFounder Strategy | ||
| Emily Faucette, Senior Relations | ||
| Matthew Pepe, Director Resource |
Talis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Talis Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (113.60) % | ||||
| Current Valuation | (38.24 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 52.15 % | ||||
| Number Of Shares Shorted | 17.96 K | ||||
| Price To Book | 0.06 X | ||||
| Price To Sales | 19.57 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |